| 13.5.1 Preparations for eczema |
| See ELHT Eczema Guidelines |
| |
Oral retinoids for severe hand eczema
|
| |
Alitretinoin, for the treatment of Chronic Eczema (TAG 177)
|
Alitretinoin is recommended, within its licensed indication, as a treatment option for adults has not responded to potent
|
topical corticosteroids if the persons has:
|
| > severe disease, as defined by the physician’s global assessment (PGA) and |
| > a dermatology life quality index (DLQI) score of 15 or more. |
| |
Oral alitretinoin is licensed for the treatment of severe chronic hand eczema unresponsive to potent topical corticosteroids,
|
in adults. Alitretinoin should only be prescribed by dermatologists, or physicians with experience in the use of systemic
|
retinoids who have full understanding of the risks of systemic retinoid therapy and monitoring requirements. Prescriptions
|
of alitretinoin for women of childbearing potential should be limited to 30 days of treatment and continuation of treatment
|
requires a new prescription. Ideally, pregnancy testing, issuing a prescription and dispensing of alitretinoin should occur on
|
the same day. Dispensing of alitretinoin should occur within a maximum of 7 days of the prescription. Pregnancy is an
|
absolute contraindication to treatment with alitretinoin. Basilea Pharmaceuticals has put together a Pregnancy Prevention
|
Programme, containing guidanceon prescribing alitretinoin to women of childbearing potential and contraceptive
|
precautions required. A treatment course of alitretinoin may be given for 12 to 24 weeks depending on response.
|
Discontinuation of therapy should be considered for patientswho still have severe disease after the initial 12 weeks of
|
treatment. In the event of relapse, patients may benefit from further treatment courses of alitretinoin. Patients should still
|
be advised to use daily emollients during therapy and once the eczema has cleared.
|
| |
RED Alitretinoin (Toctino®) capsules 10mg, 30mg
|
| |
| 13.5.2 Preparations for psoriasis |
Emollients may be sufficient for mild cases. For other cases the topical preparations may have a beneficial effect. Start with
|
low concentrations and build up. See 'Psoriasis Management in Primary Care' for further information
|
| |
| Topical preparations for psoriasis | |
| |
Vitamin D and analogues
|
GREEN Calcipotriol 50micrograms/gram ointment, scalp solution (prescribe generically)
|
GREEN Calcipotriol 50 micrograms/gram & betamethasone 0.05% ointment, gel (prescribe generically)
|
GREEN Calcipotriol 50 micrograms/gram and betamethasone 0.05% cream (Wynzora®)
|
GREEN Calcipotriol50 micrograms/gram and betamethasone cutaneous 0.05% foam (Enstilar®)
|
GREEN Tacalcitol 4 micrograms/gram ointment (Curatoderm®)
|
|
Coal tar
|
GREEN Licensed Coal tar products:
|
| lotion 5% (Exorex®) |
| scalp ointment, coal tar 12% & salicylic acid 2%, sulphur 4% (Sebco®) |
AMBER Unlicensed Coal tar products - Dermatology initiation/recommendation only
|
| e.g. coal tar in yellow soft paraffin, various strengths |
| |
Dithranol | *Please note that Dithrocream® has been discontinued and will be replaced with Specials recommended by the | | British Association of Dermatologists for Skin Disease <click here> to access the document. [AMBER traffic light] | |
GREEN Dithranol (Dithrocream®) cream 0.1%,
|
AMBER Dithranol in Lassar's paste (unlicensed product)
|
(Dermatology initiation/recommendation only) various strengths.
|
|
Oral retinoids for psoriasis - for severe resistant or complicated psoriasis, prescribed only by or under the supervision of a
|
consultant dermatologist.
|
| RED Acitretin capsules 10mg, 25mg (hospital only) |
| Salicylic acid 2% Ointment BP DISCONTINUED, no longer available as a commercial product. Secondary care may choose |
| products approved via the 'Specials recommended by by the 'British Association of Dermatologists for Skin Disease' |
| |
|
|
| | | 13.5.3 Drugs affecting the immune response | CSM Advice – Due to the risk of malignancy, Pimecrolimus 1% cream should be used as a second line treatment for mild or
| moderate atopic dermatitis where treatment with topical corticosteroids is either inadvisable or not possible.
| Tacrolimus ointment will remain a second line treatment for moderate or severe atopic dermatitis in patients who are not
| adequately responsive to or are intolerant of topical corticosteroids.
| | | Treatment with pimecrolimus cream and tacrolimus ointment should:
| | > only be initiated or recommended by specialist physicians with experience in the diagnosis and treatment of atopic | | dermatitis | | > not to be given to patients with congenital or acquired immunodeficiencies, or to patients on therapy causing | | immunosupprerssion | | > not to be applied to malignant or to potentially malignant skin lesions. | | | The frequency of administration of Tacrolimus ointment 0.03% in children should be limited to once daily. The lower
| strength of tacrolimus ointment (0.03%), should be used in adults wherever possible.
| | AMBER Tacrolimus 0.03% ointment | AMBER Pimecrolimus 1% cream
| | | Prescribers should use these products so as to minimise patient exposure and thereby reduce risk. The following are
| recommended:
| | > The medicines should be applied thinly and to affected skin surfaces only. | | > Treatment should be short term; continuous longterm use should be avoided. | | > If no improvement occurs (after 6 weeks for pimecrolimus, or 2 weeks for tacrolimus), or if the disease worsens, the |
|
| diagnosis of atopic dermatitis should be re-evaluated and other therapeutic options considered |
| |
See age restrictions for each product before prescribing.
|
| |
NICE Guidance TA534: Dupilumab is recommended as an option for treating moderate to severe atopic dermatitis in adults
|
| only if: |
> the disease has not responded to at least 1 other systemic therapy, such as ciclosporin, methotrexate, azathioprine
|
| and mycophenolate mofetil, or these are contraindicated or not tolerated. |
| > the company provides dupilumab according to the commercial arrangement |
| |
RED Dupilumab solution for injection 300mg/2mL pre-filled pens (Dupixent®▼) CCG Commissioned
|
| (BlueTec form required) |
| Back to Main Chapter |
| NICE Guidance TA681: Baricitinib is recommended as an option for treating moderate to severe atopic dermatitis in adults |
| only if: |
| > the disease has not responded to at least 1 systemic immunosuppressant, such as ciclosporin, methotrexate, |
| azathioprine and mycophenolate mofetil, or these are not suitable, and |
| > the company provides it according to the commercial agreement |
| |
| RED Baricitinib tablets 2mg, 4mg CCG Commissioned |
| (BlueTec form required) |
NICE Guidance TA814: Abrocitinib, tarlokinumab or upadacitinib for treating moderate to severe atopic dermatitis |
| Abrocitinib [*see MHRA Drug Safety Update] and upadacitinib are recommended as options for treating moderate to severe |
| atopic dermatitis that is suitable for systemic treatment in adults and young people over 12 years and over, only if: |
| > the disease has not responded to at least 1 systemic immunosuppressant, or these are not suitable |
| > the company provide abrocitinib and upadicitinib according to the commercial arrangement. |
| Tralokinumab is recommended as an option for treating moderate to severe atopic dermatitis that is suitable for systemic |
| treatment in adults, only if: |
| > the disease has not responded to at least 1 systemic immunosuppressant, or these are not suitable |
| > the company provide abrocitinib and upadicitinib according to the commercial arrangement. |
| Stop *abrocitinib, upadacitinib or tralokinumab at 16 weeks if the atopic dermatitis has not responded adequately. |
| An adequate response is: |
| > at least 50% reduction in the Eczema Area and Severity Index Score [EASI 50] from when treatment started and |
| > at least a 4-point reduction in the Dermatology Life Quality Index {DLQI] from when treatment started. |
| |
| RED *Abrocitinib [Cibinqo] see SPC ICB Commissioned [formerly CCG] |
| RED Upadacitinib [Rinvoq] ICB Commissioned [formerly CCG] |
| RED Tralokinumab [Adtralza] ICB Commissioned [formerly CCG] |
| |
MHRA Drug Safety Update [APRIL 2023: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular
|
events, malignancy, venous thromboembolism, serious infections and increased mortality.
|
| |
| Back to Main Chapter |
NICE Guidance: Atopic Eczema in Children
|
> Only specialists with experience in dermatology should start treatment with tacrolimus or pimecrolimus after
|
| discussing the risks and benefits of all other options. |
> If atopic eczema is not controlled by topical corticosteroids* or where there is a risk of serious adverse effects
|
| treatment options include: |
| > tacrolimus (0.03%) for moderate to severe atopic eczema in children aged two years and over, |
| > pimecrolimus for moderate atopic eczema on the face and neck in children aged two years and over. |
> Consider for facial atopic eczema in children requiring long-term or frequent use of mild topical corticosteroids
|
> Do not use topical tacrolimus or pimecrolimus:
|
> for mild atopic eczema,
|
| > as first-line treatment for atopic eczema of any severity, |
| > under bandages or dressings without specialist dermatological advice. |
| |
| AMBER Tacrolimus (0.03%) | | AMBER Pimecrolimus (1% cream) | |
*Unsatisfactory clinical response to adequate use of the maximum strength and potency of topical corticosteroids that is
|
appropriate for the child's age and the area being treated.
|
| |
Active plaque psoriasis in adults
|
Ustekinumab is recommended as an option, alone or in combination with methotrexate, for treating active plaque psoriasis
|
in adults as per NICE TA340 (replaces TA313)
|
| |
RED Ustekinumab solution for injection 45mg/0.5ml pfs (Stelara®) (CCG Commissioned)
|
| |
NICE Guidance: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young adults -
|
NICE TA455 Adalimumab is recommended as an option for treating plaque psoriasis in children and young people aged
|
4 years or older, only if the disease:
|
| |
> is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and
|
| > has not responded to standard systemic therapy, such as ciclosporin, methotrexate or phototherapy, or these options |
are contraindicated or not tolerated.
|
| |
Etanercept is recommended as an option for treating plaque psoriasis in children and young people aged 6years or older,
|
only if the disease:
|
> is severe as defined by a total PASI of 10 or more and
|
| > has not responded to standard systemic therapy, such as ciclosporin, methotrexate or phototherpay, or these options |
| are contraindicated or not tolerated. |
| |
Ustekinumab is recommended as an option for treating plaque psoriasis in children and young people aged 12 years or
|
older, only if the disease:
|
> is severe, as defined by a total PASI of 10 or more
|
> has not responded to standard systemic therapy, such as ciclosporin, methotrexate or photo-therapy, or these options
|
| are contraindicated or not tolerated. |
| |
Stop etanercept treatment at 12 weeks, and adalimumab and ustekinumab treatment at 16 weeks, if the psoriasis has not
|
responded adequately. An adequate response is defined as a 75% reduction in the PASI score from the start of treatment
|
| |
RED Adalimumab (Amgevita -1st line choice in new patients, Humira®,) NHS England Commissioned
|
RED Etanercept (Enbrel®) NHS England Commissioned
|
RED Ustekinumab (Stelara®) NHS England Commissioned
|
| |
Back to Main Chapter
NICE Guidance: Secukinumab for treating moderate to severe plaque psoriasis in children and young adults aged 6 to 17 years |
| NICE TA734 Secukinumab is recommended as an option for treating plaque psoriasis in children and young people aged |
| 6 to 17 years, only if: |
| > the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and |
| > the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or |
| these options are contraindicated or not tolerated and |
| > the company provides the drug according to the commercial arrangement. |
| RED Secukinumab (Cosentyx®) NHS England Commissioned |
| |
| |
Moderate to severe psoriasis NICE TA180 (updated)
|
NICE interactive flowchart - Psoriasis
|
| |
RED Risankizumab |
| NICE TA596 recommended as an option for treating plaque psoriasis in adults only if: |
| > the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and |
| a Dermatology Life Quality Index (DLQI) of more than 10 and |
| > the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and |
| phototherapy, or these options are contraindicated or not tolerated and |
| > the company provides the drug according to the commercial arrangement. |
|
RED Ustekinumab
|
NICE TA180 (updated) recommended as a treatment option for adults with plaque psoriasis
|
[Ustekinumab solution for injection 45mg/0.5ml pfs (Stelara®)] (CCG Commissioned)
|
| |
RED Dimethyl fumarate
|
NICE TA475 recommended as an option for treating moderate to severe plaque psoriasis in adults
|
[Dimethyl fumarate tablets 30mg, 120mg (Skilarence®)] CCG Commissioned Bluetec form required)
|
| |
RED Ixekizumab
|
NICE TA442 recommended as an option for treating moderate to severe plaque psoriasis in adults
|
[Ixekizumab solution for injection 80mg/1mL ] CCG Commissioned
|
| |
| RED Certolizumab pegol |
| NICE TA574 recommended as an option for treating moderate to severe plaque psoriasis in adults, only if: |
| > the disease is severe, as defined by a total Psoriasis Area and Severity Index(PASI) of 10 or more and a Dermatology Life |
| Quality Index (DLQI) of more than 10 and |
| > the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or |
| these are contraindicated or not tolerated and |
| > the lowest maintenance dosage of certolizumab pegol is used (200mg every 2 weeks) after the loading dosage |
| > the company provides the drug according to the commercial arrangement. |
| [Certolizumab pegol 200mg/1mL solution for injection pfs (Cimzia)] CCG Commissioned Bluetec form required) |
| |
| RED Tildrakizumab |
| NICE TA575 recommended as an option for treating moderate to severe plaque psoriasis in adults, only if: |
> the disease is severe, as defined by a total Psoriasis Area and Severity Index(PASI) of 10 or more and a Dermatology Life
|
| Quality Index (DLQI) of more than 10 and |
| > the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or |
| these are contraindicated or not tolerated and |
| > the company provides the drug according to the commercial arrangement. |
| [Tildrakizumab 100mg/1mL pre-filled disposable injection (Ilumetri) CCG Commissioned Bluetec form required) |
| |
NICE Guidance TA511 - Brodalumab for treating moderate to severe plaque psoriasis
|
Brodalumab is recommended as an option for treating plaque psoriasis in adults, as recommended in NICE TA511
|
RED Brodalumab solution for injection pfs 210mg/1.5mL (Kyntheum▼) (CCG Commissioned Bluetec form required)
|
| |
NICE TA521 - Guselkumab for treating moderate to severe plaque psoriasis in adults.
|
Guselkumab is recommended, as an option in NICE TA521,for treating plaque psoriasis in adults only if:
|
| |
> the disease is severe, as defined by a total Psoriasis Area and Sensitivity Index (PASI) of 10 or more and Dermatology Life
|
| Quality Index (DLQI) of more than 10 and |
| > the disease has not responded to other systemic therapies, including ciclosporin, methotrextae and PUVA |
| (psoralen and long-wave ultraviolet A radiation), or these options are contraindicated or not tolerated and |
| > the company provides the drug according to the commercial arrangement. (CCG Commissioned Bluetec form required) |
| |
Back to Main Chapter
|
| NICE TA723 Bimekizumab for treating moderate to severe plaque psoriasis |
| Bimekizumab is recommended as an option for treating plaque psoriasis in adults, only if: |
| > the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life |
| Quality Index (DLQI) of more than 10 and |
| > the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or |
| these options are contraindicated or not tolerated and |
| > the company provides the drug according to the commercial arrangement. |
RED Bimekizumab 160mg solution for injection pfs (Bimzelx®) (CCG Commissioned Bluetec form required)
|
| |
| NICE TA907 Deucravacitinib for treating moderate to severe plaque psoriasis in adults |
| Deucravacitinib is recommended as an option for treating moderate to severe plaque psoriasis in adults, only if: |
| > the Psoriasis Area and Severity Index (PASI) score is 10 or more and the Dermatology Life Quality Index (DLQI) score is more |
| |
| |
| than 10 |
| > the condition has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or |
| these options are contraindicated or not tolerated. |
| > the company provides deucravacitinib according to the commercial arrangement |
| RED Deucravacitinib ICB Commissioned Bluetec form required |
Secukinumab for the treatment of Palmoplantar Psoriasis |
| |
Secukinumab is recommended for the treatment of moderate to severe palmoplantar psoriasis that has not responded (refractory)
|
to at least two standard systemic treatments and photochemotherapy, or when standard treatments cannot be used because of
|
intolerance or contra-indications.
|
| |
RED Secukinumab
|
150mg solution for injection pfs (Cosentyx▼)
|
| 150mg solution for injection pf pen (Cosentyx▼) |
| |
| |
| Severe (refractory) Pyoderma Gangrenosum |
| See attachment [British Association of Dermatologists] |
| |
| RED Infliximab [including biosimilars] |
| |
Back to Main Chapter
|
